Evgen Pharma is a clinical stage drug development company whose lead compound, SFX-01, recently completed a Phase II clinical study in metastatic breast cancer (MBC), that showed the potential for it to be used in combination with current hormonal treatments to defer tumour resistance and delay the use of more toxic chemotherapeutic agents. A second Phase IIb study in subarachnoid haemorrhage (SAH) is due to readout in Q3 2019. SFX-01 targets two completely different biological pathways, ther
02 Apr 2019
Evgen Pharma - Initiation follows positive Phase II breast cancer data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Evgen Pharma - Initiation follows positive Phase II breast cancer data
Evgen Pharma Plc (EVG:LON) | 0.8 0 0.0% | Mkt Cap: 3.31m
- Published:
02 Apr 2019 -
Author:
Mark Brewer -
Pages:
36
Evgen Pharma is a clinical stage drug development company whose lead compound, SFX-01, recently completed a Phase II clinical study in metastatic breast cancer (MBC), that showed the potential for it to be used in combination with current hormonal treatments to defer tumour resistance and delay the use of more toxic chemotherapeutic agents. A second Phase IIb study in subarachnoid haemorrhage (SAH) is due to readout in Q3 2019. SFX-01 targets two completely different biological pathways, ther